AI assistant
ASHLAND INC. — Director's Dealing 2017
Nov 1, 2017
31616_dirs_2017-11-01_1dec975e-ca48-48a3-8cd6-1fdf68f497e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: ASHLAND GLOBAL HOLDINGS INC (ASH)
CIK: 0001674862
Period of Report: 2017-09-30
Reporting Person: WARD MICHAEL J (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock Units | $0 | Common Stock (73985) | 73985 | Direct | |
| Restricted Stock Units | $ | Common Stock (55706) | 55706 | Direct |
Footnotes
F1: 1-for-1
F2: Subject to any deferral election on timing of distribution by the reporting person under the Plan, the Common Stock Units are payable in Common Stock upon the reporting person's separation from service as a director.
F3: Balance includes 390 additional Common Stock Units acquired in lieu of cash dividends (132 acquired on June 15, 2017, and 258 on September 15, 2017), pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors, and exempt under Rule 16b-3.
F4: Each Restricted Stock Unit represents a right to receive one (1) share of Ashland Common Stock.
F5: Grant of deferred Restricted Stock Units pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors, and exempt under Rule 16b-3. The Restricted Stock Units will vest one year after date of grant. (One (1) Restricted Stock Unit in the Deferred Compensation Plan for Non-Employee Directors is the equivalent of one (1) share of Ashland Common Stock.) Subject to any deferral election on timing of distribution by the reporting person under the Plan, the reporting person may elect to receive the Restricted Stock Units in Common Stock or cash upon separation from service as a director.
F6: Balance includes 295 additional Restricted Stock Units acquired in lieu of cash dividends (101 acquired on June 15, 2017, and 194 on September 15, 2017), and exempt pursuant to Rule 16b-3.